Inventor
Robert M. Burk
Inventor
Laguna Beach, CA, US
Overview
Patents· 163 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds23%
A61KPreparations for medical, dental or toiletry purposes20%
C07CAcyclic or carbocyclic compounds19%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
C07BGeneral methods of organic chemistry1%
A61QSpecific use of cosmetics or similar toiletry preparations1%
A61FFilters implantable into blood vessels1%
A61LMethods or apparatus for sterilising materials or objects in general1%
C08LCompositions of macromolecular compounds1%
PatentTitleYear
10,875,845Compounds and methods for the treatment of ocular disorders202010,668,081Prostamide-containing intraocular implant202010,329,284Ester prodrugs of gamma-lactams and their use201910,117,877Methods for fat reduction20189,981,938Quaternary ammonium alkyl esters as stable prodrugs20189,889,142'Prostamide-containing intraocular implant'20189,890,118'Prostamides for the treatment of glaucoma and related diseases'20189,795,615'Methods for fat reduction'20179,573,926'Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use'20179,540,357'15-aryl prostaglandins as EP4 agonists, and methods of use thereof'20179,499,478'Substituted cyclopentanes for inducing hair growth'20169,433,627'Prostamides for the treatment of glaucoma and related diseases'20169,427,401'Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes'20169,340,534'Compounds and methods for treating ocular diseases'20169,315,486'Therapeutic cyclopentanols, compositions thereof, and methods for use thereof'20169,289,413'Prostamide-containing intraocular implant'20169,090,595'Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes'20159,024,042'Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes'20159,006,464'Substituted cyclopentanes having prostaglandin activity'20158,865,766'Ester derivatives of bimatoprost compositions and methods'20148,686,025'Therapeutic lactams'20148,648,213'Prostamides for the treatment of glaucoma and related diseases'20148,609,658'N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof'20138,557,860'Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20138,546,603'Substituted cyclopentanes having prostaglandin activity'20138,487,091'Substituted cyclopentanes having prostaglandin activity'20138,455,547'Substituted cyclopentanes having prostaglandin activity'20138,389,566'Prostaglandins and analogues as agents for lowering intraocular pressure'20138,198,318'Therapeutic amides'20128,193,373'Therapeutic compounds'20128,168,680'Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20128,158,676'Substituted cyclopentanes having prostaglandin activity'20128,124,648'Therapeutic lactams'20128,063,033'Therapeutic beta-lactams'20118,044,092'Therapeutic compounds'20118,017,655'Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'20117,994,195'Therapeutic substituted piperidone compounds'20117,985,767'Therapeutic amides'20117,964,634'Therapeutic compounds'20117,964,595'Thiophenyl prostaglandin derivatives for treating glaucoma and ocular hypertension'20117,960,378'Therapeutic compounds'20117,960,379'Therapeutic compounds'20117,960,431'Thiophenyl prostaglandin derivatives for treating glaucoma and ocular hypertension'20117,935,825'Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain'20117,932,420'Sulfonamides'20117,915,316'Sulfonamides'20117,906,552'Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20117,897,629'Therapeutic compounds'20117,872,045'Combination therapy for glaucoma treatment'20117,868,035'Therapeutic esters'20117,863,318'Prostaglandins and analogues as agents for lowering intraocular pressure'20117,863,319'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20117,799,821'Therapeutic compounds'20107,772,392'Therapeutic substituted β-lactams'20107,732,443'Therapeutic substituted cyclopentanes'20107,674,786'Therapeutic β-lactams'20107,612,082'Prostaglandin EP4 antagonists'20097,585,895'Therapeutic substituted cyclopentanes'20097,557,095'Therapeutic compounds'20097,514,462'ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists'20097,482,475'Therapeutic lactams'20097,473,704'Cyclohexyl prostaglandin analogs as EP4-receptor agonists'20097,429,615'Cyclohexyl prostaglandin analogs as EP4-receptor agonists'20087,427,685'Therapeutic substituted cyclopentanes'20087,326,698'Prostaglandin analogs'20087,314,890'Sulfonamides'20087,273,883'Prostaglandin EP4 antagonist'20077,235,586'Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents'20077,223,746'Omega cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists'20077,217,725'Prostaglandin D2 antagonist'20077,214,678'Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain'20077,186,744'Prostamides for the treatment of glaucoma and related diseases'20077,183,324'2,3,4-substituted cyclopentanones as therapeutic agents'20077,183,310'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20077,101,906'2,3,4-substituted cyclopentanones as therapeutic agents'20067,101,904'Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20067,098,223'Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain'20067,022,726'ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists'20067,019,149'Thromboxane ligands without blood clotting side effects'20067,015,243'Cyclohexyl prostaglandin analogs as EP4-receptor agonists'20067,005,442'8-azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents'20066,956,057'EP4 agonists as agents for lowering intraocular pressure'20056,906,097'8-azaprostaglandin analogs as agents for lowering intraocular pressure'20056,825,221'Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain'20046,818,779'Thromboxane ligands without blood clotting side effects'20046,812,240'8-azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents'20046,767,920'3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure'20046,734,201'8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents'20046,734,206'3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure'20046,716,876'Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'20046,716,864'Interheteroaryl 7-oxabicyclic 2.2.1heptane oxazoles as prostaglandin F2 antagonists'20046,710,072'-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists'20046,706,755'Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents'20046,680,337'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20046,670,485'Prostanoic acid derivatives as agents for lowering intraocular pressure'20036,602,900'Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20036,586,462'-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists'20036,573,294'8-azaprostaglandin analogs as agents for lowering intraocular pressure'20036,573,390'Cyclopentane heptan (ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20036,538,018'3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure'20036,531,504'Prostanoic acid derivatives as agents for lowering intraocular pressure'20036,511,999'Interheteroaryl 7-oxabicyclic 2.2.1heptane oxazoles as prostaglandin F2 antagonists'20036,509,364'Interphenylene 7-oxabicyclic 2.2.1 heptane oxazoles as prostaglandin F2 antagonists'20036,476,064'Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents'20026,462,077'Thromboxane ligands without blood clotting side effects'20026,414,022'Cyclopentane(ENE)heptenoic or heptenoic acids and derivatives thereof useful as therapeutic agents'20026,410,591'3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure'20026,407,250'Interphenylene 7-oxabicyclic 2.2.1 heptane oxazoles as prostaglandin F2a antagonists'20026,403,649'Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents'20026,395,787'Ocular hypotensive lipids'20026,380,250'Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents'20026,380,251'Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents'20026,376,533'Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists'20026,369,089'Interheteroaryl 7-oxabicyclic 2.2.1heptane oxazoles as prostaglandin F2 antagonists'20026,359,181'Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents'20026,310,087'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20016,307,092'Cyclopentane, 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents'20016,303,658'Cyclopentane heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'20016,291,522'Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents'20016,258,844'Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents'20016,248,773'Cyclopentane heptan(ene)oic acid, 2-heteroarylalk(en)yl derivatives as therapeutic agents'20016,248,783'Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents'20016,204,287'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20016,160,129'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20006,124,344'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20006,096,902'Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20006,090,845'Thromboxane ligands'20006,037,364'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'20006,017,953'Thromboxane ligands'20005,990,138'Cyclopentane (ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'19995,972,991'Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'19995,906,989'Cyclopentane(ENE) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'19995,874,460'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19995,834,498'Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents'19985,814,657'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19985,808,101'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19985,798,378'Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'19985,773,654'7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these compounds'19985,750,784'Method for effecting vasodilation with (1,5-inter) aryl prostaglandin derivatives'19985,741,812'Thromboxane ligands without blood clotting side effects'19985,741,810'Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents'19985,714,621'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19985,710,288'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19985,688,819'Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'19975,681,848'Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'19975,674,910'7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds'19975,661,178'Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives'19975,658,897'Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents'19975,654,329'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19975,650,431'Thromboxane ligands without blood clotting side effects'19975,607,978'Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'19975,587,391'Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'19965,552,434'7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these compounds'19965,545,665'Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents'19965,523,296'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19965,516,791'7-[carboxyakyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1]octane and derivatives thereof'19965,506,262'Cholesterol lowering compounds'19965,468,778'Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives'19955,416,106'7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof'19955,385,945'7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds'19955,369,125'Cholesterol-lowering agents'19945,369,127'1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents'19945,352,708'Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents'1994Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1994–2020Patents assigned to ALLERGAN INC (133)· patent assignee history
1994–2020Based in Laguna Beach, CA, US· patent location history
1994–2011Based in Irvine, CA, US· patent location history
1999–2002Patents assigned to ALLERGAN SALES INC (25)· patent assignee history
2002–2007Based in Laguna Niguel, CA, US· patent location history
2010–2015Patents assigned to BURK ROBERT M (17)· patent assignee history
2010–2015Patents assigned to DONDE YARIV (5)· patent assignee history
2011–2014Patents assigned to OLD DAVID W (6)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ALLERGAN INC | 133 | 1994–2020 |
| ALLERGAN SALES INC | 25 | 1999–2002 |
| BURK ROBERT Mself | 17 | 2010–2015 |
| OLD DAVID W | 6 | 2011–2014 |
| DONDE YARIV | 5 | 2010–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| Laguna Beach, California, US | 152 | 1994–2020 |
| Irvine, California, US | 9 | 1994–2011 |
| Laguna Niguel, California, US | 2 | 2002–2007 |